There is a chance of recurrence of your CRC (5-50% depending on your original stage of CRC).1 The COLVERA test, coupled with visits with your doctor, is designed to detect early recurrence of CRC while reducing the need for invasive testing. COLVERA is a blood test that detects two genes in circulating tumor DNA (ctDNA). With three times more detection than carcinoembryonic antigen (CEA) testing, this early detection allows for a more extensive range of therapies and peace of mind.
1 NCCN Clinical Practice Guidelines (Colon and Rectal Cancer), 2020
The COLVERA Test is a simple process:
COLVERA is a blood test that detects two specific colorectal cancer genes, BCAT1 and/or IKZF1, released in the blood from colorectal tumors. By identifying specific tumor DNA, instead of a protein, COLVERA has been three times more effective in detecting early CRC.
CEA is a test that has been used for over three decades to detect a specific protein present when colorectal cancer develops. However, CEA has caused false positives or does not detect CRC early enough for more treatments. There is a need for better testing.
If your healthcare provider determines that COLVERA is suitable for you, your provider can order the test. Your blood can be drawn in the physician’s office or at a Quest Diagnostics® Patient Service Center (PSC) near your provider’s office.
There is no need to change or modify your diet for testing
COLVERA only requires two 10 mL tubes of whole blood. This is equivalent to about 1.5 tablespoons of blood.
Your healthcare provider will receive your test results from the Clinical Genomics Laboratory within 10 business days.
COLVERA® results are reported as detected, not detected or indeterminate.